
This story is not a valuation, an appraisal, or tax or legal advice. Multiples marked "CP math" are Cannabis Professional calculations from company filings, shown below.
The fight for Aurora Cannabis won't set your store's price. It does show what buyers pay extra for, and none of it is a storefront.
Two buyers want Aurora. Canada's Organigram signed a deal on Nov. 3 to buy it for C$7.80 a share, about C$561 million. Curaleaf, the U.S. multistate operator, has a competing offer open until Dec. 4 and says it will raise it.
By our math, the Organigram price works out to about 1.3 times Aurora's annualized sales and about 8x to 13x its annualized adjusted EBITDA, depending on the period. Single U.S. stores have been selling for far less on both counts, as we found in How Much Is My Dispensary Worth?
Here's why, and what changes for you now.
What's On The Table
Organigram's deal. C$7.80 per Aurora share, in cash, Organigram stock, or a mix of both, with limits on how much of each. The companies say that's a 93% premium to Aurora's price on Aug. 10, the day before Curaleaf went public with its bid, and 21% above the value of Curaleaf's offer on Nov. 2. Aurora's board backs it unanimously. (Organigram/Aurora release, Nov. 3, 2026)
Curaleaf's offer. US$1.00 in cash plus 0.4013 of a Curaleaf share for each Aurora share. Curaleaf valued that at US$5.00 a share on Oct. 2, an 86% premium. About 80% of it is Curaleaf stock, so its value moves with Curaleaf's share price. (Curaleaf, Oct. 5, 2026; Curaleaf 8-K, Oct. 6, 2026) Aurora's board has rejected it twice.
The clock. Curaleaf's offer expires at 11:59 p.m. Mountain Time on Dec. 4 unless it's extended or changed. Aurora shareholders vote on the Organigram deal at a virtual special meeting on Dec. 23 (Aurora meeting notice, SEC). Organigram expects to close in January 2027 if shareholders, regulators and a British Columbia court sign off.
Curaleaf's next move. Curaleaf says it has cleared competition review in Canada and Germany, the only two places it needed it (Curaleaf, Nov. 10, 2026). On its Nov. 4 earnings call, CEO Boris Jordan said Curaleaf is "going to improve our bid substantially," but that it won't raise the offer materially without due diligence access, as first reported by The Deep Dive.
What Buyers Are Actually Paying For
Aurora doesn't run U.S. dispensaries. It's a medical cannabis company: 96% of its C$86.0 million in net revenue last quarter was medical, and C$61.4 million of that came from outside Canada, mainly Germany and Poland (Aurora Q2 fiscal 2027 results, Nov. 5, 2026).
The buyers say what they want, and it isn't shelf space:
Licenses and approved facilities. Organigram points to Aurora's EU-GMP certified manufacturing and its patient network in Canada, Europe, Australia and New Zealand.
Savings from combining. Organigram cites more than C$50 million in identified synergies. Curaleaf cites at least US$40 million in expected annual cost savings.
A clean balance sheet. Aurora reported C$133.0 million in cash, cash equivalents and short-term investments, and no debt besides leases.
A second bidder. Curaleaf's hostile bid started the clock in August. Organigram's deal came out of the sale process Aurora ran after that. Each move pushed the price up.
That's the same list a store buyer works from, at a smaller scale. "A lot of times deal structure is dictated by state regulations, but as a general rule an asset deal would result in a higher value than an equity deal," Calvin Shannon, CPA, CVA, of BGM Advisory, told Cannabis Professional earlier this month.

The Math: Why Aurora's Multiple Isn't Your Multiple
All Aurora figures are in Canadian dollars, for the quarter ended Sept. 30, 2026 (Aurora's fiscal second quarter of 2027). Annualized means one quarter times four, which is a rough shortcut, not a reported full-year figure. These are Cannabis Professional calculations.
Step | Figure | Source / math |
|---|---|---|
Equity value (Organigram deal) | C$561M | Organigram/Aurora release |
Less cash, equivalents, short-term investments | − C$133.0M | Aurora Q2 FY27 |
Plus lease liabilities (Aurora's only debt) | + C$21.4M | Aurora Q2 FY27 MD&A |
Enterprise value (estimate) | ≈ C$449M | CP math |
Annualized net revenue | C$86.0M × 4 = C$344.1M | CP math |
Annualized adjusted EBITDA | C$14.0M × 4 = C$56.0M | CP math |
EV ÷ annualized revenue | ≈ 1.3x | 449 ÷ 344 |
EV ÷ annualized adjusted EBITDA | ≈ 8.0x | 449 ÷ 56 |
In U.S. dollars, C$561 million is about US$397 million at the 1.4115 exchange rate Organigram used. Revenue and price have to be in the same currency; converting both gives the same multiples.
Now set that against a store.
On cash earnings. For a store sale that isn't distressed, Charles Alovisetti, a partner at Vicente LLP, told Cannabis Professional this month: "I would say 3.5x EBITDA is a pretty typical multiple" (CP, Nov. 13). "I think now you're typically seeing a multiple based on EBITDA for non-distressed transactions," he said. By our math, Organigram's price values Aurora at about 8x to 13x adjusted EBITDA, depending on the period: about 8x if you annualize its latest quarter, about 13x on its last six months. Either way, it's more than double the store benchmark.

On sales. Disclosed U.S. store deals in 2025 and 2026 have run from about 0.2x to 1.2x sales, by our earlier count. The top of that range was New Jersey's Union Chill, a store with more than $11 million in annualized sales. Aurora's 1.3x sits just above the best store deal, and Aurora is a global medical company with factories, not a shop.
For a $1 million store. Our Nov. 13 analysis put a very rough band of $200,000 to $1.2 million on a store with about $1 million in sales. Nothing in the Aurora fight moves that band. Don't take Aurora's multiple and apply it to your sales.
Competition among buyers. Curaleaf raised its offer 25% in October, then Organigram came in 21% above that. One serious buyer is a negotiation. Two is a market.
A buyer who needs what you have. "If you're a small MSO and you're looking to expand your footprint in another state, I suspect you're going to get pushed on the multiple because of that desire," Joshua Horn, partner and co-chair of cannabis law at Fox Rothschild LLP, told Cannabis Professional earlier this month.

A license that can move. Aurora's German units needed government sign-off before Curaleaf could buy them. Your license may need it too, and some can't be sold at all. "It depends on the state. Maryland, where I do a fair amount of work, you can sell the license. Pennsylvania, strictly forbidden," Horn said.
Cash flow a buyer can see. "Even if they're not making a profit… companies are buying on positive cash flow," Horn said.
Paper vs. cash. Most of Curaleaf's offer is Curaleaf stock, and Aurora's board has questioned what that stock is worth. Store owners face the same thing with stock, seller notes and earn-outs. Count those below face value when you compare offers.
What Changes For You Now
The Aurora fight doesn't raise your store's value. It's a reminder of how the market is set up right now.
Big buyers are spending, selectively. Horn described the broader market this way: "The M&A space, with some exceptions, has been relatively quiet. What you're seeing is larger companies buying up smaller companies at a discount, quite frankly, because companies are hard pressed to make money. It's been soft for a couple of years."
Store prices are still down from the boom. "It's a distressed market now. So most transactions... much lower valuations," Alovisetti said.
Diligence decides the price. Curaleaf says it won't bid much higher until it sees Aurora's books. Your buyer will want the same. Alovisetti's advice: "Think about the regulatory and structural issues before you start talking to potential buyers... You don't want it to come out during the diligence process."
Tax baggage can be managed. "People can still do deals with significant tax exposure if there's someone creditworthy who's willing to stand behind the indemnity, because that'll de-risk it significantly for the buyer," Alovisetti said.
Watch Dec. 4. If Curaleaf raises its offer, the new terms will show what a U.S. operator will pay for licensed, cash-generating assets. If it lets the offer lapse, Aurora's Dec. 23 vote settles the fight.
If A Buyer Calls, Pull These Together First
Not legal, tax, or valuation advice. Use it to set the agenda with your CPA and attorney.
☐ Three years of financials and tax returns, plus a normalized EBITDA (or SDE if you run the store yourself) that backs out owner pay, related-party rent and one-time costs.
☐ Monthly sales and cash flow for the last 12 to 24 months, so a buyer sees consistency, not one good quarter.
☐ Your license file: license type (medical, adult-use or both), whether your state lets it transfer as an asset or only through a sale of the entity, and the state's change-of-ownership timeline.
☐ Your 280E position by year and any open tax exposure, with your CPA's read on how a buyer would treat it.
☐ Your lease, with assignment and change-of-control terms, and a sense of whether your landlord will work with a buyer.
☐ Your cap table, operating agreement, and any buy-sell or transfer restrictions among owners.
☐ Compliance history: inspections, notices of violation and any open enforcement items.
☐ Key contracts: vendors, POS, security and banking, and whether any can be ended on a sale.
☐ A short list of the buyers who would want your license or your location most, so one call becomes two.
☐ A rule for comparing offers: cash at closing first, then notes, stock and earn-outs, each counted below face value.
Sources (All Accessed Nov. 19, 2026)
Organigram and Aurora joint release, Nov. 3, 2026: https://auroraxorganigram.com/documents/organigram-aurora-press-release.pdf
Curaleaf, "Curaleaf Enhances Offer to Acquire Aurora Cannabis," Oct. 5, 2026: https://ir.curaleaf.com/2026-10-05-Curaleaf-Enhances-Offer-to-Acquire-Aurora-Cannabis
Curaleaf Form 8-K, Oct. 6, 2026 (Notice of Variation; expiry 11:59 p.m. MT Dec. 4): https://www.sec.gov/Archives/edgar/data/1756770/000110465926113907/tm2623363d17_8k.htm
Aurora Notice of Change to Directors' Circular (SEC exhibit; ~80% stock mix, board rejection): https://www.sec.gov/Archives/edgar/data/1683541/000110465926116021/tm2627570d1_ex1-10.htm
Curaleaf, competition clearances, Nov. 10, 2026: https://ir.curaleaf.com/2026-11-10-Curaleaf-Receives-All-Required-Competition-Law-Clearances-for-Proposed-Acquisition-of-Aurora-Cannabis
Aurora Form 6-K, Q2 fiscal 2027 (financial statements + MD&A), Nov. 5, 2026: https://www.sec.gov/Archives/edgar/data/1683541/000162828026070546/form6-k20260930q22027.htm (exhibits mda20260930q22027.htm, fs20260930q22027.htm)
Aurora Q2 FY27 release (Business Wire): https://www.businesswire.com/news/home/20261105890209/en/Aurora-Cannabis-Announces-Fiscal-2027-Second-Quarter-Results
Computershare notice of Aurora special meeting (Dec. 23, 2026; record date Nov. 18), Nov. 9, 2026: https://www.sec.gov/Archives/edgar/data/1683541/000110465926124555/tm2629252d1_ex99-1.htm
The Deep Dive (JP Alegre), Nov. 5, 2026, partner reporting (Jordan earnings-call quote): https://thedeepdive.ca/curaleaf-ceo-says-company-will-raise-aurora-bid-after-organigram-deal-demands-due-diligence-first/
Ordo Verde, "Earnings Week Review," Nov. 10, 2026, partner reporting (cross-check only; US$ conversions at 1.3993): https://ordoverde.beehiiv.com/p/earnings-week-review-how-does-the-cohort-compare
Cannabis Professional, "How Much Is My Dispensary Worth?", Nov. 13, 2026: https://cannabisprofessional.com/p/what-is-a-one-store-dispensary-worth-vireo-s-all-stock-fluent-deal-offers-clues-not-a-price-tag-5859